The risk of pancreatic cancer (PC) is increased in melanoma-prone families but the causal relationship between germline CDKN2A mutations and PC risk is uncertain, suggesting the existence of non-CDKN2A factors. One genetic possibility involves patients having mutations in multiple high-risk PC-related genes; however, no systematic examination has yet been conducted. We used next-generation sequencing data to examine 24 putative PC-related genes in 43 PC patients with and 23 PC patients without germline CDKN2A mutations and 1001 controls. For each gene and the four pathways in which they occurred, we tested whether PC patients (overall or CDKN2A+ and CDKN2A− cases separately) had an increased number of rare nonsynonymous variants. Overall, w...
Pancreatic cancer (PC), particularly its most common form, pancreatic ductal adenocarcinoma (PDAC), ...
Pancreatic cancer (PC), particularly its most common form, pancreatic ductal adenocarcinoma (PDAC), ...
Pancreatic cancer (PC) has a poor prognosis, with a five-year survival rate of less than 9%. To inve...
The risk of pancreatic cancer (PC) is increased in melanoma-prone families but the causal relationsh...
The risk of pancreatic cancer (PC) is increased in melanoma-prone families but the causal relationsh...
Background: The p16-Leiden founder mutation in the CDKN2A gene is the most common cause of Familial ...
BACKGROUND: The p16-Leiden founder mutation in the CDKN2A gene is the most common cause of Familial ...
BACKGROUND: The p16-Leiden founder mutation in the CDKN2A gene is the most common cause of Familial ...
BACKGROUND: Pathogenic variants in the CDKN2A gene are generally associated with the development of ...
Rare truncating BRCA2 K3326X (rs11571833) and pathogenic CHEK2 I157T (rs17879961) variants have prev...
Rare truncating BRCA2 K3326X (rs11571833) and pathogenic CHEK2 I157T (rs17879961) variants have prev...
Rare truncating BRCA2 K3326X (rs11571833) and pathogenic CHEK2 I157T (rs17879961) variants have prev...
Rare truncating BRCA2 K3326X (rs11571833) and pathogenic CHEK2 I157T (rs17879961) variants have prev...
Pancreatic cancer (PC), particularly its most common form, pancreatic ductal adenocarcinoma (PDAC), ...
BackgroundPathogenic variants in the CDKN2A gene are generally associated with the development of me...
Pancreatic cancer (PC), particularly its most common form, pancreatic ductal adenocarcinoma (PDAC), ...
Pancreatic cancer (PC), particularly its most common form, pancreatic ductal adenocarcinoma (PDAC), ...
Pancreatic cancer (PC) has a poor prognosis, with a five-year survival rate of less than 9%. To inve...
The risk of pancreatic cancer (PC) is increased in melanoma-prone families but the causal relationsh...
The risk of pancreatic cancer (PC) is increased in melanoma-prone families but the causal relationsh...
Background: The p16-Leiden founder mutation in the CDKN2A gene is the most common cause of Familial ...
BACKGROUND: The p16-Leiden founder mutation in the CDKN2A gene is the most common cause of Familial ...
BACKGROUND: The p16-Leiden founder mutation in the CDKN2A gene is the most common cause of Familial ...
BACKGROUND: Pathogenic variants in the CDKN2A gene are generally associated with the development of ...
Rare truncating BRCA2 K3326X (rs11571833) and pathogenic CHEK2 I157T (rs17879961) variants have prev...
Rare truncating BRCA2 K3326X (rs11571833) and pathogenic CHEK2 I157T (rs17879961) variants have prev...
Rare truncating BRCA2 K3326X (rs11571833) and pathogenic CHEK2 I157T (rs17879961) variants have prev...
Rare truncating BRCA2 K3326X (rs11571833) and pathogenic CHEK2 I157T (rs17879961) variants have prev...
Pancreatic cancer (PC), particularly its most common form, pancreatic ductal adenocarcinoma (PDAC), ...
BackgroundPathogenic variants in the CDKN2A gene are generally associated with the development of me...
Pancreatic cancer (PC), particularly its most common form, pancreatic ductal adenocarcinoma (PDAC), ...
Pancreatic cancer (PC), particularly its most common form, pancreatic ductal adenocarcinoma (PDAC), ...
Pancreatic cancer (PC) has a poor prognosis, with a five-year survival rate of less than 9%. To inve...